Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer

Launched by NATERA, INC. · Sep 1, 2010

Keywords

ClinConnect Summary

If you meet the criteria below, you may be a candidate for this study. To participate in the study you must:

* Be a healthy, pre-menopausal female, 35-42 years of age
* Have a history of less than 3 consecutive miscarriages and no more than one failed IVF cycle
* Agree to use Ferring Pharmaceutical products during stimulation
* Agree to be randomly assigned to either the arm of the study receiving PGS (TEST arm)or the arm receiving no additional testing (CONTROL arm)

Additional screening will be conducted to determine if you are eligible to enroll.

All subjects who qualify and enroll wil...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Must agree to a follow-up visit at approximately 4-8 weeks gestation and a follow up phone call at 20 and 40 weeks gestation/livebirth. For patients assigned to the TEST group must agree to PGD testing and collection of buccal swab sample on newborn
• • At least 10 eggs retrieved
• • Must agree to use only Ferring products during stimulation
• • Normal uterine cavity detected on hysterosalpingogram (HSG), saline infusion sonogram (SIS), or hysteroscopy
• • Signed consent form
• Exclusion Criteria:
• • FSH ≥10 IU/L within past year prior to screening
• • 2 or more previously failed IVF cycles
• • Gestational or surrogate carrier, donor oocyte, donor sperm
• • History of recurrent pregnancy loss (3 or more consecutive miscarriages)
• • Severe male factor infertility defined as ejaculate sperm of \< 1million sperm/ml, or sperm obtained through testicular biopsy
• • Gender selection as primary indication
• • Maternal disease that is not clinically stable and known to impact the ability to become pregnant or carry a pregnancy to term (lupus, chronic liver or kidney disease, body mass index (BMI) \>35, uncontrolled hypertension, anti-phospholipid antibody, thrombophilia, insulin dependent diabetes)
• • Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests
• • Participation in any experimental drug study within 30 days prior to Screening
• • Prior hypersensitivity to any of the protocol drugs
• • Known history conveying increased risk for chromosome abnormality (beyond maternal age) or genetic disease in offspring